BR112015023381A2 - composição de liberação imediata de sovaprevir, composição de sovaprevir de 200 mg, núcleo de comprimido de sovaprevir e comprimido de sovaprevir revestido - Google Patents

composição de liberação imediata de sovaprevir, composição de sovaprevir de 200 mg, núcleo de comprimido de sovaprevir e comprimido de sovaprevir revestido

Info

Publication number
BR112015023381A2
BR112015023381A2 BR112015023381A BR112015023381A BR112015023381A2 BR 112015023381 A2 BR112015023381 A2 BR 112015023381A2 BR 112015023381 A BR112015023381 A BR 112015023381A BR 112015023381 A BR112015023381 A BR 112015023381A BR 112015023381 A2 BR112015023381 A2 BR 112015023381A2
Authority
BR
Brazil
Prior art keywords
sovaprevir
tablet
composition
coated
immediate release
Prior art date
Application number
BR112015023381A
Other languages
English (en)
Inventor
Phadke Avinash
Shah Gautam
Hsing-Chung Chu Jennifer
Original Assignee
Achillion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Achillion Pharmaceuticals Inc filed Critical Achillion Pharmaceuticals Inc
Publication of BR112015023381A2 publication Critical patent/BR112015023381A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

resumo composição de liberação imediata de sovaprevir, composição de sovaprevir de 200 mg, núcleo de comprimido de sovaprevir e comprimido de sovaprevir revestido a divulgação inclui núcleos de comprimido compreendendo sovaprevir e um inibidor de crescimento de cristal selecionado a partir de hidroxipropilmetilcelulose (hpmc), hpc (hidroxipropilcelulose), succinato de acetato de hipromelose (hpmcas), polivinil pirrolidona (pvp), copovidona (pvp-va), um copolímero de ácido metacrílico e acrilato de etila, ou qualquer combinação destes anteriormente mencionados, em que a proporção de sovaprevir para o inibidor do crescimento de cristal é de aproximadamente 40:60 (p/p) a aproximadamente 60:40 (p/p). a divulgação inclui ainda comprimidos revestidos. a divulgação também inclui métodos para o tratamento de hcv com os comprimidos descritos no presente documento. 1/1
BR112015023381A 2013-03-15 2014-03-13 composição de liberação imediata de sovaprevir, composição de sovaprevir de 200 mg, núcleo de comprimido de sovaprevir e comprimido de sovaprevir revestido BR112015023381A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361790645P 2013-03-15 2013-03-15
PCT/US2014/025969 WO2014151547A1 (en) 2013-03-15 2014-03-13 Sovaprevir tablets

Publications (1)

Publication Number Publication Date
BR112015023381A2 true BR112015023381A2 (pt) 2017-07-18

Family

ID=50439520

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015023381A BR112015023381A2 (pt) 2013-03-15 2014-03-13 composição de liberação imediata de sovaprevir, composição de sovaprevir de 200 mg, núcleo de comprimido de sovaprevir e comprimido de sovaprevir revestido

Country Status (12)

Country Link
US (1) US20140271855A1 (pt)
EP (1) EP2968171A1 (pt)
JP (1) JP2016512845A (pt)
KR (1) KR20160005022A (pt)
CN (1) CN105358137A (pt)
AU (1) AU2014233897A1 (pt)
BR (1) BR112015023381A2 (pt)
CA (1) CA2905423A1 (pt)
EA (1) EA201591787A1 (pt)
IL (1) IL241350A0 (pt)
SG (1) SG11201507468TA (pt)
WO (1) WO2014151547A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0714343A2 (pt) 2006-07-13 2013-03-19 Achillion Pharmaceuticals Inc peptÍdeos de 4-amino-4-oxobutanoil como inibidores de replicaÇço viral
US9227952B2 (en) 2013-03-15 2016-01-05 Achillion Pharmaceuticals, Inc. Sovaprevir polymorphs and methods of manufacture thereof
CN104258411A (zh) * 2014-09-19 2015-01-07 安徽山河药用辅料股份有限公司 一种硅化微晶纤维素复合辅料及其制备方法
CN105943536A (zh) * 2016-05-06 2016-09-21 杭州容立医药科技有限公司 一种固体分散体的制备方法及其应用
EP3860849A4 (en) * 2018-10-05 2022-06-22 ISP Investments LLC SMOOTH HIGH SOLIDS FILM COATING COMPOSITION COMPRISING WATER-SOLUBLE CELLULOSE ETHER, AND METHOD FOR PREPARING THE SAME

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101506223B (zh) * 2006-07-13 2013-05-22 艾其林医药公司 作为病毒复制抑制剂的4-氨基-4-氧代丁酰基肽
JP2011530532A (ja) * 2008-08-07 2011-12-22 シェーリング コーポレイション 固体分子分散物中のｈｃｖプロテアーゼインヒビターの薬学的処方物
US8927576B2 (en) * 2009-04-06 2015-01-06 PTC Therpeutics, Inc. HCV inhibitor and therapeutic agent combinations
JP5781706B2 (ja) * 2011-12-29 2015-09-24 アッヴィ・アイルランド・アンリミテッド・カンパニー Ｈｃｖ阻害剤を含む固体組成物
WO2013116592A1 (en) * 2012-02-01 2013-08-08 Kadmon Pharmaceuticals, Llc Once daily treatment of hepatitis c with ribavirin and taribavirin

Also Published As

Publication number Publication date
EP2968171A1 (en) 2016-01-20
IL241350A0 (en) 2015-11-30
EA201591787A1 (ru) 2015-12-30
JP2016512845A (ja) 2016-05-09
CN105358137A (zh) 2016-02-24
AU2014233897A1 (en) 2015-10-01
KR20160005022A (ko) 2016-01-13
WO2014151547A1 (en) 2014-09-25
SG11201507468TA (en) 2015-10-29
CA2905423A1 (en) 2014-09-25
US20140271855A1 (en) 2014-09-18

Similar Documents

Publication Publication Date Title
BR112015023381A2 (pt) composição de liberação imediata de sovaprevir, composição de sovaprevir de 200 mg, núcleo de comprimido de sovaprevir e comprimido de sovaprevir revestido
TN2013000220A1 (en) Orally disintegrating tablet
MX2022002952A (es) Formulaciones de liberacion modificada de 2-[3-[4-amino-3-(2-fluor o-4-fenoxi-fenil)pirazolo[3,4-d]pirimidin-1-il]piperidina-1-carbo nil]-4-metil-4-[4-(oxetan-3-il)piperazin-1-il]pent-2-enenitrilo.
MX2015012092A (es) Capsulas y comprimidos solidos de benzonatato de liberacion modificada.
JP2017537168A5 (pt)
RS54329B1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING RIFAXIMINE, PROCEDURES FOR THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF VAGINAL INFECTIONS
MX2021016109A (es) Metodos y composiciones particularmente para el tratamiento del trastorno por deficit de atencion.
BR112013009255A2 (pt) forma de dosagem oral de dissolução rápida de vacina que usa amido
JO3543B1 (ar) تراكيب حمض أميني إصدار معدل تعطى عن طريق الفم
PH12018501237A1 (en) Isoindole compounds
AR077546A1 (es) Formulaciones de comprimidos de 3-cianoquinolina y usos de los mismos
NO20076328L (no) Anvendelse av antagonister for oksytocin og/eller vasopressin
JP2020511419A5 (pt)
AR081935A1 (es) Tableta con nucleo recubierto de liberacion controlada
GEP201706743B (en) Oral formulation for the treatment of cardiovascular diseases
CL2016000183A1 (es) Composición farmacéutica anti-tuberculosis estable en una forma de un comprimido redispersable que comprende gránulos de isoniazid y gránulos de rifapentina y su proceso de preparación
CO2018002046A2 (es) Nueva composición oral de libreación retardada dual de dexlansoprazol
JP2017019880A5 (pt)
PH12015502119A1 (en) Sovaprevir tablets
PH12014502325B1 (en) Sustained release tablet containing levodropropizine and method for preparing same
PH12014502609B1 (en) Multilayer coating form of orally administered pharmaceutical composition containing omega-3 fatty acid or alkyl ester thereof and statin based drug
ECSP16005208A (es) Composición farmacéutica anti-tuberculosis estable en una forma de un comprimido recubierto que comprende gránulos de isoniazid y gránulos de rifapentina y su proceso de preparación
BR112016008288A2 (pt) receptor fc gama solúvel para tratamento de doenças autoimunes bolhosas
MX2014007523A (es) Anillo vaginal que comprende meloxicam y un agente modulador de la liberacion del principio activo, util como anticonceptivo de uso continuo en mujeres.
CL2015002251A1 (es) Composiciones farmacéuticas que contienen dexketoprofeno y tramadol

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]